Eli Lilly Q4 revenue rises 43% to $19.3 billion; 2026 EPS guidance $33.50-$35.00
Eli Lilly reported fourth-quarter 2025 revenue of $19.3 billion, up 43% from a year earlier, with reported EPS of $7.39, up 51%. The company also issued full-year 2026 guidance of $80 billion to $83 billion in revenue and non-GAAP EPS of $33.50 to $35.00, which gives shareholders a baseline for the coming year.
Key points
- Q4 2025 revenue was $19.3 billion, up 43%, led by Mounjaro and Zepbound volume growth
- Q4 2025 reported EPS was $7.39 (up 51%); non-GAAP EPS was $7.54 (up 42%), both including $0.52 of acquired IPR&D charges
- 2026 guidance: revenue of $80 billion to $83 billion and non-GAAP EPS of $33.50 to $35.00, assuming about 894 million shares outstanding
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 04, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.